Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Medical Imaging Research & Development, ArthroLab Inc., Montreal, Quebec, Canada.
Osteoarthritis Cartilage. 2019 Aug;27(8):1163-1173. doi: 10.1016/j.joca.2019.04.016. Epub 2019 May 16.
There is a need to identify reliable biomarkers that can predict knee osteoarthritis (OA) progression. We investigated a panel of adipokines and some related inflammatory factors alone and their ratios for their associative value at assessing cartilage volume loss over time and symptoms in obese [High body mass index (BMI)] and non-obese (Low BMI) OA subjects.
Human OA serum was from the Osteoarthritis Initiative Progression subcohort. Baseline levels of adiponectin (high and low molecular weight forms), adipsin, chemerin, leptin, visfatin, C-reactive protein (CRP), interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) were evaluated with specific assays. Cartilage volume was assessed at baseline and 48 months by quantitative magnetic resonance imaging (MRI), and symptoms using baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Data were analysed by linear regression with confounding factors at baseline, followed by multiple comparison adjustment.
The levels of the nine biomarkers and their ratios (36) were studied. Among High BMI subjects, only the ratio adipsin/MCP-1 was associated with cartilage volume loss over time in the lateral compartment [β, -2.95; 95% confidence interval (CI), -4.42, -1.49; P = 0.010], whereas MCP-1 was associated with WOMAC pain (-1.74; -2.75, -0.73; P = 0.030) and the ratio CRP/MCP-1 with WOMAC pain (0.76; 0.37, 1.14; P = 0.023), function (2.43; 1.20, 3.67; P = 0.020) and total (3.29; 1.58, 5.00; P = 0.027). No associations were found for biomarkers or ratios in Low BMI OA.
In this study, the ratio adipsin/MCP-1 was found to be associated with the knee structural changes and that of CRP/MCP-1 with symptoms in obese OA subjects. Our data further underline the relevance of ratios as biomarkers to a stronger association to OA progression and symptoms.
需要确定可靠的生物标志物，以预测膝骨关节炎（OA）的进展。我们研究了一组脂肪因子和一些相关的炎症因子，单独评估它们及其比值在评估肥胖[高体重指数（BMI）]和非肥胖（低 BMI）OA 受试者的软骨体积随时间丢失和症状方面的关联价值。
人类 OA 血清来自骨关节炎倡议进展子队列。使用特定的测定法评估了基线水平的脂联素（高分子量和低分子量形式）、 adiposin、 chemerin、瘦素、 visfatin、C 反应蛋白（CRP）、白细胞介素-8（IL-8）和单核细胞趋化蛋白-1（MCP-1）。通过定量磁共振成像（MRI）在基线和 48 个月时评估软骨体积，并使用基线 Western Ontario 和 McMaster 大学骨关节炎指数（WOMAC）评分评估症状。通过线性回归分析，在基线时考虑混杂因素，然后进行多重比较调整。
研究了 9 种生物标志物及其比值（36）。在高 BMI 受试者中，只有 adipsin/MCP-1 比值与外侧室软骨体积随时间的丢失相关[β，-2.95；95%置信区间（CI），-4.42，-1.49；P=0.010]，而 MCP-1 与 WOMAC 疼痛相关（-1.74；-2.75，-0.73；P=0.030），CRP/MCP-1 比值与 WOMAC 疼痛（0.76；0.37，1.14；P=0.023）、功能（2.43；1.20，3.67；P=0.020）和总评分（3.29；1.58，5.00；P=0.027）相关。在低 BMI OA 中，未发现生物标志物或比值与 OA 相关。
在这项研究中，发现 adiposin/MCP-1 比值与肥胖 OA 受试者的膝关节结构变化相关，而 CRP/MCP-1 比值与症状相关。我们的数据进一步强调了比值作为生物标志物与 OA 进展和症状相关性更强的相关性。
